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Abstract
Background: There has been significant progress in the last two decades on the design of chimeric antigen
receptors (CAR) for adoptive immunotherapy targeting tumor-associated antigens. Structurally CARs consist of a
single chain antibody fragment directed against a tumor-associated antigen fused to an extracellular spacer and
transmembrane domain followed by T cell cytoplasmic signaling moieties. Currently several clinical trials are
underway using gene modified peripheral blood lymphocytes (PBL) with CARs directed against a variety of tumor
associated antigens. Despite the improvements in the design of CARs and expansion of the number of target
antigens, there is no universal flow cytometric method available to detect the expression of CARs on the surface of
transduced lymphocytes.
Methods: Currently anti-fragment antigen binding (Fab) conjugates are most widely used to determine the
expression of CARs on gene-modified lymphocytes by flow cytometry. The limitations of these reagents are that
many of them are not commercially available, generally they are polyclonal antibodies and often the results are
inconsistent. In an effort to develop a simple universal flow cytometric method to detect the expression of CARs,
we employed protein L to determine the expression of CARs on transduced lymphocytes. Protein L is an
immunoglobulin (Ig)-binding protein that binds to the variable light chains (kappa chain) of Ig without interfering
with antigen binding site. Protein L binds to most classes of Ig and also binds to single-chain antibody fragments
(scFv) and Fab fragments.
Results: We used CARs derived from both human and murine antibodies to validate this novel protein L based
flow cytometric method and the results correlated well with other established methods. Activated human PBLs
were transduced with retroviral vectors expressing two human antibody based CARs (anti-EGFRvIII, and anti-
VEGFR2), two murine antibody derived CARs (anti-CSPG4, and anti-CD19), and two humanized mouse antibody
based CARs (anti-ERBB2, and anti-PSCA). Transduced cells were stained first with biotin labeled protein L followed
by phycoerythrin (PE)-conjugated streptavidin (SA) and analyzed by flow cytometry. For comparison, cells were
stained in parallel with biotin conjugated goat-anti-mouse Fab or CAR specific fusion proteins. Using protein L, all
CAR transduced lymphocytes exhibited specific staining pattern ranging from 40 to 80% of positive cells
(compared to untransduced cells) and staining was comparable to the pattern observed with anti-Fab antibodies.
Conclusion: Our data demonstrate the feasibility of employing Protein L as a general reagent for the detection of
CAR expression on transduced lymphocytes by flow cytometry.
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Adoptive immunotherapy using T lymphocytes geneti-
cally modified to express a chimeric antigen receptor
(CAR) combines the beneficial effects of both antibody
and T-cell mediated immune responses. Typically CARs
consists of a single chain antibody fragment (scFv)
directed against tumor associated cell surface antigen
fused to extracellular spacer and transmembrane
domains followed by various combination of cytoplasmic
signaling moieties such as CD3 zeta, CD28, OX40 or 4-
1BB (Figure 1B). Currently a number of early phase clin-
ical trials are underway using gene-modified peripheral
blood lymphocytes (PBL) with CARs directed against a
variety of tumor antigens [1]. Since the first CAR was
reported in 1989 [2], there have been significant
improvements in the design of CAR for optimal antigen
recognition, enhanced T cell function and survival in
vivo [3]. The number of target antigens that have been
shown to be suitable for CAR based therapies is steadily
expanding, indicating the potential promise of this
approach in tumor immunotherapy [3,4]. Despite the
advancements in the design of CARs and expansion of
number of target antigens, there is no universal flow
cytometric method available to detect the expression of
CARs on the surface of lymphocytes.
To determine the level of expression of CARs on gene
modified lymphocytes by flow cytometry, T cells have to
be stained with specific ligands or antibodies conjugated
with fluorochromes. For example, anti-ERBB2 and anti-
VEGFR2 specific CAR expression is detected by ERBB2-
fragment crystallizable (Fc) or VEGFR2-Fc fusion proteins,
respectively, followed by fluorochrome conjugated anti-
human IgG Fc antibody [5,6]. In other cases anti-human
IgG-Fab; or anti-mouse IgG-Fab antibodies are used in
flow cytometric analysis [7,8]. However, variations
between polyclonal antibody preparations often lead to
inconsistent results. Furthermore, staining with many dif-
ferent kinds of antibodies can be time consuming and
labor intensive. Given the limitations of existing
approaches the need for a reliable and simple method for
the detection of CAR expression by flow cytometry on
lymphocytes is evident. To address this issue, we employed
a protein L based assay as a general method to determine
the expression of various types of CARs on transduced
lymphocytes.
Protein L is a bacterial surface protein isolated from
Peptostreptoccocus magnus that selectively binds to vari-
able light chains (kappa chain) of immunoglobulin with-
out interfering with antigen binding property of the
antibodies (Abs) [9,10]. Protein L specifically binds Ig
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Figure 1 A. Illustration showing the binding sites (arrows) of Protein A, Protein G, and Protein L to the heavy and light chain regions
of the antibody. Protein L binding is restricted to those antibodies that contain kappa light chains. B. Schema showing Protein L binding to
the kappa light chain of a single chain variable fragment (scFv) portion of a chimeric antigen receptor (CAR). TM, transmembrane region of CAR;
vH, variable heavy chain; vL, variable light chain.
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was suggested (Figure 1A). It consists of 719 amino acid
residues with a molecular weight of 76 kD and binds to
light chain of all classes of immunoglobulin such as IgG,
IgM, IgA, IgE, IgD, and Fab fragments [11] unlike other
antibody-binding proteins such as protein A and G
which bind to Fc portion of immunoglobulin (Figure
1A). It also binds to single-chain antibody fragments
(scFv) making it a convenient reagent to detect the cell
surface expression of CARs.
In this study, we tested the possibility of using protein
L as a general reagent to detect the expression of CARs
on transduced PBLs by flow cytometry. We employed
CARs constructed from human as well as murine
derived scFvs to validate this new flow cytometric
method. Our data presented here support the feasibility
of employing protein L as a general reagent to detect
the cell surface expression of multiple CARs by flow
cytometry.
Methods
PBLs and retroviral transduction
PBLs used in the study were obtained from patients under
institutional review board approved clinical protocols at
the Surgery Branch, National Cancer Institute, National
Institutes of Health, Bethesda, MD. All patients gave
informed consent for sample procurement. PBLs were sti-
mulated with AIM-V medium (Invitrogen, Carlsbad, CA)
supplemented with 5% human AB serum (Valley Biomedi-
cals, Winchester, VA), 300 IU/ml IL2 (Aldesleukin Proleu-
kin
®, Novartis, Basel, Switzerland) and 50 ng/ml OKT3
(MuromonAB-CD3, Orthoclone OKT3, Ortho Biotech,
Raritan, NJ) for two days before transduction with retro-
viral supernatants expressing various CAR constructs.
MSGV1-based retroviral vectors expressing CARs against
tumor-associated antigens ERBB2, VEGFR2, CSPG4, and
CD19 were previously described in detail [5-8]. Anti-
E G F R v I I Ia n dP S C AC A R sa r eb a s e do nah u m a na n da
humanized mouse antibody respectively. Vector produc-
tion and PBL transduction was also previously described
in detail [5,7]. Briefly, 2 ml of viral vector supernatants
expressing the various CARs were diluted with an equal
volume of AIM-V medium supplemented with 5% human
AB serum and added into one well of 6-well plates pre-
viously coated with RetroNectin (Takara Bio Inc., Otsu,
Japan). Plates were then loaded with retroviral superna-
tants by centrifugation at 32°C, 2000 g for 2 hours (Sorvall
Legend RT, Newtown, CT). Transduction was carried out
by removing the vector supernatant and adding 2 × 10
6
activated PBLs per well, centrifugation at 1000 g for 10
minutes and the plates were then incubated at 37°C with
5% CO2. The transduction procedure was repeated on the
following day. Five to seven days after transduction, PBLs
were used for FACS analysis using protein-L and other
antibodies as described below.
Fluorescence-activated cell sorting (FACS) staining
Biotinylated protein L was purchased from GeneScript
(Piscataway, NJ) reconstituted in phosphate buffered saline
(PBS) at 1 mg/ml and stored at 4°C. Biotin-SA-conjugated
goat-anti-mouse IgG (Fab) used to detect murine CARs
(CD19 and CSPG4) was from Jackson ImmunoResearch
laboratories, Inc, (West Grove, PA), ERBB2-Fc fusion pro-
tein specific to human anti-ERBB2 CAR was obtained
from R&D Systems (Minneapolis, MN). For FACS stain-
ing, 1 × 10
6 cells were harvested and placed into a 5 ml
snap-cap tube (Becton Dickinson, Franklin Lakes, NJ), and
washed three times with 3 ml of ice-cold 1 × PBS contain-
ing 4% bovine serum albumin (BSA) (BSA fraction V,
Fisher Scientific, Fair Lawn, NJ) wash buffer. In order to
achieve optimal staining, all possible carry-over immuno-
globulin in culture media supplemented with serum
should be removed from the sample by washing three
times. After wash, cells were resuspended in 0.2 ml of the
ice-cold wash buffer and incubated either with 1 μgo f
protein L, 1 μg of ERBB2-Fc or 20 μg of goat-anti-mouse
Abs respectively at 4°C for 45 minutes. Cells were washed
with 3 ml of the ice-cold wash buffer three times, and
then incubated (in the dark) with 10 μl of phycoerythrin
(PE) -conjugated streptavidin (SA-PE, 5 μg/ml) (BD
Bioscience, San Jose, CA) in 0.2 ml of the wash buffer for
samples with protein L and goat-anti-mouse IgG. Cells
incubated with human ERBB2-Fc were stained with 10 μl
PE labeled goat-anti-human Fc IgG (Jackson ImmunoRe-
search laboratories, Inc, West Grove, PA). Immunofluores-
cence staining was analyzed as the relative log fluorescence
of live cells, determined using a FACscan flow cytometer
(BD). A combination of forward angle light scatter and
propidium iodide (PI) staining was used to gate out the
dead cells, and 1 × 10
5 cells were analyzed. All FACS data
was analyzed using FlowJo 8.1.1 software (TreeStar,
Ashland, OR).
Results and discussion
We utilized the specific binding property of protein L to
immunoglobulin light chains and scFvs to develop a
general flow cytometric method for the determination of
CAR expression on genetically engineered lymphocytes.
Figure 1A depicts the binding of protein L on the light
chains of antibodies and scFvs compared to other bac-
terial proteins A and G, which bind to Fc portion of the
immunoglobulin. To test if protein L binds specifically
on PBL transduced with CARs (Figure 1B), and to opti-
mize the concentration of protein L needed for staining,
we performed a titration experiment to determine the
optimal concentration of biotinylated Protein L required
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CAR (based on a humanized murine antibody) or an
anti-EGFRvIII CAR (based on a human antibody) were
used for this titration experiment. Protein L was added
at 0.01, 0.05, 0.1, 1.0, 1.5, 2.0 or 3 μg for staining of 1 ×
10
6 lymphocytes in 0.2 ml 1 × PBS containing 4% BSA.
Following addition of SA-PE, CAR expressing lympho-
cytes exhibited a specific staining pattern (compared to
control SA-PE stained cells) as measured by the flow
cytometry (Figure 2). Optimal staining was observed at
1 μg protein L/sample containing 1 × 10
6 lymphocytes
expressing either murine or human CARs. Protein L
binding was highly specific to CAR expression in lym-
phocytes and displayed a concentration dependent bind-
ing as measured by the FACS analysis.
Following optimization of the concentration of bioti-
nylated protein L required for staining of the PSCA-
CAR and EGFRvIII-CAR expressing lymphocytes, we
next tested general applicability of this method using
lymphocytes transduced with five different CARs. Acti-
vated human PBLs were transduced with two human
antibody-derived CARs directed against EGFRvIII,
VEGFR2, two murine mAb-based CARs reactive with
CSPG4 and CD19, and one humanized mouse antibody-
based CAR recognizing ERBB2. Seven days following
transduction, lymphocytes were stained with 1 μgo f
biotin-labeled protein L followed by incubation with PE-
conjugated streptavidin and analyzed by flow cytometry.
As shown in Figure 3A, CAR specific protein L staining
was observed in all five PBL expressing CARs, whereas
only the background staining was seen in the control
cells that were either untransduced (UT) or T cell
receptor (TCR) transduced PBL.
Consistent results were obtained when the experiments
were repeated with CAR engineered PBL from different
donors (a total of four donors were analyzed, data not
shown). We have found protein L to be an extremely use-
ful reagent for the analysis of CAR-engineered cells, and
have reliably used protein L to detected CAR expression
with 6 out of 6 different CAR vectors. While Protein L
effectively binds most subtypes of kappa light chains
(with the exception of VII), it does not bind to lambda
(l) light chains, but these account for only a minority of
antibodies (Nilson, B.H., et al. 1992, 1993).
In order to further validate the reliability of protein L as
a suitable reagent to determine the expression of CARs on
PBL, protein L staining was compared with two estab-
lished methods (Figure 3B and 3C). As shown in Figure
3B, the percentage of CAR positive PBL determined by
protein L staining (52%) was in close agreement with
experimental data obtained from goat anti-mouse Fab
staining used to determine the percentage of CSPG4 CAR
expressing cells (68%). In another experiment lymphocytes
expressing an ERBB2-CAR were stained either with pro-
tein L or ERBB2-Fc/goat-anti-human IgG. A comparable
staining pattern was again observed in FACS analysis (78%
vs. 88% for protein L and the ERBB2-Fc respectively). To
determine the intra-assay variation, the experiments were
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Figure 2 Titration of Protein L concentration required for optimal FACS analysis. Activated PBLs were transduced with retroviral
vector expressing anti-PSCA-CAR or anti-EGFRvIII-CAR and analyzed for CAR expression on day 8. One million cells were stained with
0.01, 0.05, 0.1, 1.0, 1.5, 2.0 or 3.0 μg/sample of biotinylated Protein L. The cells were then washed and stained with phycoerythrin (PE)-conjugated
streptavidin (SA). Cells were analyzed using a FACScan flow cytometer and the data analyzed with FlowJo software. Result of a representative
experiment from four independent experiments is presented. No-Prot-L, samples stained with SA-PE alone.
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Figure 3 A. FACS analysis of PBL transduced with various human or murine monoclonal antibody (mAb) based CARs.F i v ed a y s
following the transduction of PBLs with retroviral vectors expressing CARs targeting ERBB2, EGFRvIII, VEGFR2, CSPG4 antigen or CD19, cells were
first stained with biotinylated protein L followed by PE-conjugated streptavidin (SA). Untransduced (UT) cells and T cell receptor (TCR) transduced
cells were used as negative controls. Cells were analyzed using a FACScan flow cytometer and the data analyzed with FlowJo software. B.
Comparison of Protein L staining to other established methods of detection of CAR expression. PBL expressing murine mAb-based anti-CSPG4
CAR were analyzed for CAR expression using goat-anti-mouse fragment antigen binding (Fab) versus protein L. These results are representative
of five independent determinations. C. Humanized mAb-based anti-ERBB2 CAR transduced PBL were analyzed for CAR expression using a CAR-
specific ERBB2-fragment crystallizable (Fc) fusion protein versus protein L. The result presented here is a representative experiment of three
independent determinations.
Zheng et al. Journal of Translational Medicine 2012, 10:29
http://www.translational-medicine.com/content/10/1/29
Page 5 of 6repeated with samples from different donors and compar-
able results obtained (data not shown). These results sug-
gest that CAR expression in PBL could be reliably
detected using a protein L based FACS assay.
Conclusion
In this study, we established the suitability of protein L
staining as a novel and general reagent for the determi-
nation of CAR expression in PBL. Furthermore, staining
is rapid and uses fewer reagents than comparable proto-
cols. The protein L based FACS assay described in this
study allowed us to readily determine the expression of
CARs on transduced PBL using six unrelated CAR con-
structs of human, mouse, and chimeric origin. This
method could be a useful tool for the quantification of
nearly any CAR expressed in transduced a lymphocyte
population during preclinical development, and poten-
tially in clinical samples from cancer patients treated
with lymphocytes engineered to express CARs in human
gene therapy clinical trials.
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